Prognostic value of age-adjusted Charlson comorbidity index in patients with cervical cancer
10.3760/cma.j.cn113030-20250507-00175
- VernacularTitle:校正年龄后的查尔森合并症指数对宫颈癌患者的预后评估
- Author:
Xiaochun WANG
1
;
Shouyu WANG
1
;
Liuyang XU
1
;
Liangliang SHI
1
;
Kehua PANG
1
;
Peng WU
1
;
Bo LIU
1
;
Jun YANG
1
Author Information
1. 新乡医学院第一附属医院放射治疗技术科，新乡 453100
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Age-adjusted Charlson comorbidity index;
Carcinoma,squamous cell carcinoma;
Overall survival;
Progression-free survival;
Radica
- From:
Chinese Journal of Radiation Oncology
2025;34(11):1124-1131
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the prognostic value of the age-adjusted Charlson comorbidity index (ACCI) in patients with stage IIB cervical squamous cell carcinoma (CSCC) who received radical concurrent chemoradiotherapy (rCCRT).Methods:Clinical data of 115 patients with stage IIB CSCC who underwent rCCRT at the First Affiliated Hospital of Xinxiang Medical University from January 2017 to January 2023 were retrospectively analyzed. Fourteen clinical factors, including ACCI, were assessed. Univariate and multivariate Cox regression analyses were performed to identify the independent prognostic factors for progression-free survival (PFS) and overall survival (OS). The optimal cut-off value for ACCI was determined using the receiver operating characteristic (ROC) curve analysis, and patients were divided into the high ACCI (ACCI > 3) and low ACCI (ACCI ≤ 3) groups. Survival differences between two groups were evaluated using Kaplan-Meier curves and compared by log-rank tests.Results:Multivariate Cox regression analysis revealed that ACCI was an independent prognostic factor for both PFS and OS ( HR=3.405, 95% CI: 1.108-10.467, P=0.032; HR=4.732, 95% CI: 1.363-16.425, P=0.014). Significant differences were observed in PFS and OS between the high and low ACCI groups ( P=0.023 and 0.003, respectively). The median PFS was 44 months in the high ACCI group and 56 months in the low ACCI group. The 2-year and 3-year PFS rates were 81.9% and 80.1% in the high ACCI group, and 94.4% and 94.4% in the low ACCI group, respectively. The median OS was 46 months in the high ACCI group and 56 months in the low ACCI group. The 2-year and 3-year OS rates were 88.3% and 84.7% in the high ACCI group, and 94.4% and 94.4% in the low ACCI group, respectively. Conclusions:For patients with stage IIB CSCC receiving rCCRT, ACCI is an independent and significant prognostic factor, with patients in the high ACCI group exhibiting worse prognosis.
